arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BioRestorative Therapies, Inc.

BRTX

$0.21 0.00 (+0.71%) at close

18 Visible periods

27 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, BioRestorative Therapies, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.9M

Dividend Yield —

Revenue Growth -10.3% ↘

Op. Margin —

ROIC -3465.0% ↘

FCF / Share $-1.21 ↘

Trailing P/E —

Price / Book 5.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

18-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$359.70K

↓ -10.3% —

Net Income Profit after all expenses

$-14.24M

↓ -58.6% —

FCF / Share Free cash flow per share

$-1.21

↓ -12.9% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -3465.0% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.77x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Revenue Growth YoY (%)	-10.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-229%)	175.0% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2088%)	21.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+171%)	160.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1905%)	-40.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-603%)	-40.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-610%)	17.1% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+114%)	37.0% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+363%)	122.8% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1435%)	-94.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1278%)	51.2% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+540%)	24661.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+308171%)	-89.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1215%)	—	—	—	—	—
EPS Growth YoY (%)	-36.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	53.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	51.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	86.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-58.6% Weak ↓ Weak Declining Year-over-year change in net income	13.8% Fair ↑ Fair Improving Year-over-year change in net income	43.7% Excellent ↑ Excellent Improving Year-over-year change in net income	58.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-293.0% Weak ↓ Weak Declining Year-over-year change in net income	23.0% Good ↑ Good Improving Year-over-year change in net income	-17.0% Weak → Weak Stable Year-over-year change in net income	-32.5% Weak ↓ Weak Declining Year-over-year change in net income	-9.4% Weak ↑ Weak Improving Year-over-year change in net income	-9.0% Weak → Weak Stable Year-over-year change in net income	-41.8% Weak ↓ Weak Declining Year-over-year change in net income	2.8% Caution ↑ Caution Improving Year-over-year change in net income	12.0% Fair ↑ Fair Improving Year-over-year change in net income	13.2% Fair ↑ Fair Improving Year-over-year change in net income	-232.8% Weak Weak Year-over-year change in net income	-89.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-12.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	31.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	8.4% Fair Fair Year-over-year change in free cash flow	39.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	44.3% Excellent → Excellent Stable Compound annual revenue growth over 3 years	105.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	23.7% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-2.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-25.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-1.7% Weak ↑ Weak Improving Compound annual revenue growth over 3 years	52.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-43.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-42.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	178.7% Excellent Excellent Compound annual revenue growth over 3 years	243.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	36.1% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	25.3% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	5.6% Fair ↑ Fair Improving Compound annual revenue growth over 5 years	8.1% Good ↑ Good Improving Compound annual revenue growth over 5 years	4.8% Fair ↓ Fair Declining Compound annual revenue growth over 5 years	-34.3% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	-20.8% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	131.2% Excellent Excellent Compound annual revenue growth over 5 years	39.0% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
FCF / Net Income (x)	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.33x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.17x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	0.49x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.38x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.34x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Return on Invested Capital (%)	-3465.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-107.0% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-120.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-94.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-96.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	163.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	52.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	69.9% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	96.8% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	123.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	144.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	56.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	56.2% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	85.6% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	76.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	298.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-383.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-94.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-120.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-115.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-117.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-63.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-575.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-641.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-476.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-492.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-355.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-291.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-343.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-439.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1607.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-441.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	-105.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-802%)	-104.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-794%)	-116.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-879%)	-205.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1468%)	—	114.7% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+664%)	144.9% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+866%)	138.1% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+821%)	172.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1051%)	202.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1252%)	81.1% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+441%)	86.0% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+474%)	127.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+748%)	204.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1263%)	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Debt to Equity (x)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.26x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-144%)	—	—
Interest Coverage (x)	—	—	—	—	-14.49x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	—	-23.73x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-170.76x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-477.49x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-256.04x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-27.20x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-17.26x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-12.80x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-9.42x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-13.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	-85.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-1.51M	$-547.89K	$-884.38K	$-1.71M	$-21.03M	—	—	—	—	—	—	—	—	—	—	$196.88K	—	—
Debt / EBITDA (x)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.10x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Revenue per Share (USD)	$0.04	$0.05	$0.03	$0.03	$0.04	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.58	$-1.16	$-2.47	$-5.11	$-37.30	—	—	—	—	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.21	$-1.07	$-1.56	$-1.71	$-2.83	—	—	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.04	$1.23	$2.13	$4.30	$6.13	$-1.86	$-0.16	$-0.74	$-1.12	$-1.06	$-1.18	$-4.06	$-0.35	$-0.35	$-0.01	$-0.00	—	—
Tangible Book Value per Share (USD)	$-0.02	$1.14	$1.97	$4.09	$5.97	$-2.79	$-0.17	$-0.81	$-1.26	$-1.27	$-1.49	$-4.67	$-0.41	$-0.42	$-0.01	$-0.00	—	—
Basic Weighted Avg Shares (shares)	8.99M	7.76M	4.22M	3.62M	1.19M	—	—	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Working Capital (USD)	$-586.03K	$7.40M	$8.78M	$14.69M	$21.10M	$2.14M	$-13.65M	$-9.07M	$-7.83M	$-5.77M	$-5.32M	$-8.41M	$-7.26M	$-2.78M	$-3.79M	$-997.78K	—	—
LT Debt (USD)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$196.88K	—	—
Total Equity (USD)	$356.74K	$8.53M	$10.00M	$15.83M	$21.60M	$-1.33M	$-12.78M	$-8.64M	$-6.84M	$-5.00M	$-3.91M	$-6.89M	$-6.69M	$-5.14M	$-3.69M	$-744.22K	$-51.09K	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗	FY 2010 Dec 31, 2010 10-K ↗	FY 2009 Dec 31, 2009 10-K ↗	FY 2008 Dec 31, 2008 10-K ↗
Sales/Revenue/Turnover (USD)	$359.70K	$401.00K	$145.80K	$119.80K	$46.00K	$77.00K	$130.00K	$111.00K	$81.00K	$36.35K	$628.91K	$416.00K	$1.68K	$15.59K	$0.00	—	—	—
Depreciation Expense (USD)	$120.24K	$99.31K	$75.99K	$42.21K	$89.11K	$121.38K	$217.36K	$240.37K	$259.26K	$258.43K	$213.78K	$96.69K	$104.81K	$90.40K	$90.41K	$48.36K	—	—
Net Income, GAAP (USD)	$-14.24M	$-8.98M	$-10.42M	$-18.49M	$-44.30M	$-11.27M	$-14.65M	$-12.52M	$-9.44M	$-8.64M	$-7.92M	$-5.59M	$-5.75M	$-6.54M	$-7.53M	$-2.26M	$-1.20M	—
Operating Cash Flow (USD)	$-10.79M	$-8.23M	$-6.43M	$-5.91M	$-3.33M	$-1.96M	$-6.92M	$-5.10M	$-3.85M	—	—	—	—	$-3.18M	$-2.81M	$-729.22K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 65 quarters

BioRestorative Therapies, Inc.

Analytical Summary

18-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare BRTX with peers